A Phase 1a/1b, multicenter, open-label study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of PLN-101095 alone and in combination with pembrolizumab in adults with advanced or metastatic solid tumors following progression on immune checkpoint inhibitor therapy

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2026-526116-36-00

Enrollment

Registered

2026-07-29

Start date

Unknown

Completion date

Unknown

Last updated

2026-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced or metastatic solid tumours

None listed

Sex/Gender

All

Age

18 Years to No maximum

None listed

Source: EU CTIS · Data processed: Jul 30, 2026